Researchers from the University of Santiago de Compostela and University of Porto have reported the discovery of a novel acetylcholinesterase (AChE) inhibitor, MJM-255.
Iama Therapeutics Srl has sought new, selective inhibitors of solute carrier family 12 member 2 (NKCC1) to treat autism, Down syndrome and brain disorders featuring chloride (NKCC1/solute carrier family 12 member 5 [KCC2]) imbalance.
Synthetic cells (SCs) armed with recombinant growth factors could contribute to tissue regeneration and healing by promoting angiogenesis. This technology opens the door to its application in other therapies such as transplants that require the remodeling or formation of new blood vessels. In addition, they mark the way to produce intracorporeal biological drugs or the inhibition of the angiogenesis process itself when it comes to blocking the irrigation of a tumor.
Pancreatic β cells are the only cells in the body that produce insulin, and are the cells whose malfunctioning is the proximate cause of diabetes. Consequently, repairing or replacing β cells is one of the major goals of diabetes research. In type I diabetes, where the immune system destroys β cells, need to be replaced outright. In type II diabetes, β cells “disappear” in another way. There is ample evidence that under conditions of chronic high blood sugar, such cells dedifferentiate, becoming less β cell-like over time.
Medshine Discovery Inc. has patented gonadotropin-releasing hormone receptor (GnRHR) antagonists reported to be useful for the treatment of endometriosis and uterine fibroids.
F. Hoffmann-La Roche Ltd. has divulged pyrimidin-2-yl sulfonamide derivatives acting as uracil nucleotide/cysteinyl leukotriene receptor (GPR17; P2Y-Like) antagonists reported to be useful for the treatment of obesity, Alzheimer's disease, Parkinson's disease, meningitis, encephalitis, ischemia, demyelinating diseases and schizophrenia.
Tsd Life Sciences Co. Ltd. has discovered imidazopyridine derivatives acting as protein kinase inhibitors and reported to be useful for the treatment of cancer.
Korea University Research and Business Foundation (KURBF) has identified adamantyl derivatives acting as dipeptidyl peptidase 4 (DPP4; CD26) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, Parkinson's disease, nonalcoholic steatohepatitis (NASH), rheumatoid arthritis, aortic valve stenosis and cerebrovascular and dermatological disorders.
Emulate Inc. has launched a new adeno-associated virus (AAV) transduction application for the Liver-Chip that enables gene therapy researchers to test the delivery efficiency and safety of AAV vectors in a validated, human-relevant model of the liver and get results in weeks.
RSS
